Producer
Bachem Holding AG
Swiss peptide CDMO; largest independent peptide API manufacturer globally; $1B+ expansion at Bubendorf Switzerland; key GLP-1 API supplier for generics and biosimilar programs
1
Inputs supplied
0
Goods downstream
1
Facilities
0
Stories
What they make
1 input Bachem Holding AG supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
GLP-1 & Metabolic Peptide APIs
45%Oncology & Specialty Peptide APIs
28%Contract Development & Manufacturing (CDMO)
18%Research & Biochemicals
9%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Origin2023
Bachem AG, a small Swiss peptide chemistry company founded in Bubendorf in 1971 by Peter Grogg, spent its first three decades as an unremarkable supplier of research-grade peptides to academic labs. Then GLP-1 receptor agonists (first approved in 2005 with Amylin/Eli Lilly's exenatide/Byetta) began transforming diabetes care, and Bachem had quietly become the world's largest independent peptide API manufacturer using solid-phase peptide synthesis (SPPS) — a method invented by Robert Merrifield, who won the 1984 Nobel Prize in Chemistry for it. When Novo Nordisk's semaglutide (Ozempic 2018, Wegovy 2021) triggered the global obesity drug revolution, Bachem controlled roughly 60-70% of external GLP-1 peptide API manufacturing capacity. The 2022-2024 Ozempic shortage was at its core a Bachem manufacturing bottleneck: Novo Nordisk had contracted so much of Bachem's capacity that other GLP-1 drug developers could not find sufficient API supply. Bachem's revenue nearly doubled from CHF 385M (2020) to CHF 700M+ (2023) as a result — the most dramatic pharmaceutical supply chain concentration event of the decade, centering on a 50-year-old Swiss factory in a town of 7,000 people.
Bachem AG ↗Did you know2024
Bachem's peptide manufacturing capacity is structurally shared across two entirely separate markets: the blockbuster obesity/diabetes drug market (GLP-1 agonists) and the oncology market (LHRH agonists like leuprolide for prostate/breast cancer, somatostatin analogs like octreotide for neuroendocrine tumors). These oncology peptide APIs are not optional — patients with metastatic prostate cancer or carcinoid syndrome have no alternative therapies. When Novo Nordisk's semaglutide demand surge consumed Bachem's capacity through 2022-2024, oncology drug manufacturers quietly faced extended lead times for leuprolide and octreotide APIs. The FDA's drug shortage database recorded multiple LHRH agonist shortages during this period, though pharma companies did not publicly attribute them to upstream peptide API competition with obesity drugs. Bachem is thus a single point of failure simultaneously serving life-extending cancer drugs and the most commercially lucrative weight-loss drugs ever developed.
US FDA ↗